MEIP - MEI Pharma expands early-stage zandelisib trial in specific blood cancer cohorts

MEI Pharma ([[MEIP]] +6.4%) has announced that the Phase 1b trial arm exploring zandelisib in combination with BeiGene's Brukinsa (zanubrutinib) has completed the safety evaluation stage in patients with B-cell malignancies and is expanding into disease specific B-cell malignancy cohorts.Anticipated milestones for 2021:Enrollment in Phase 2 TIDAL study evaluating zandelisib as a monotherapy in relapsed or refractory follicular lymphoma, to complete around the end of Q1 of 2021, with initiation of a second arm of the study in relapsed or refractory marginal zone lymphoma, expected in Q1 of 2021. Topline data anticipated in Q4 of 2021.Plans to initiate Phase 3 study of zandelisib in combination with rituximab in pre-treated follicular and marginal zone lymphoma patients, in mid-2021.Data from Phase 1 program evaluating voruciclib in combination with venetoclax, for B-cell malignancies and acute myeloid leukemia, anticipated in 2021.The company also confirmed that it has a cash runway to fund operations through

For further details see:

MEI Pharma expands early-stage zandelisib trial in specific blood cancer cohorts